Vaccine therapy of colorectal cancer patients with tumor antigens - Cancer vaccines
by Ullenhag, Gustav
VAT included - FREE Shipping
Do you like this product? Spread the word!
$79.99 incl. VAT
Only 1 items available Only 1 items available
Check other buying options
1 Offer for $91.54
Sold by Dodax EU
$91.54 incl. VAT
Delivery: between Thursday, October 7, 2021 and Monday, October 11, 2021
For the first time two tumor-associated antigens were evaluated as adjuvant therapy in combination with granulocyte colony stimulating factor (GM-CSF) for patients with colorectal cancer. The rst study involved immunization with the protein, carcinoembryonic antigen (CEA) during one year. This vaccination regimen induced a strong immunoglobulin 1 (IgG1) and IgG4 and a moderate IgG2 response against CEA. The humoral as well as the T cell responses were protracted up to 36 months. The dose of CEA had no or modest effect on these responses. The anti-CEA IgG titers related signi cantly to survival. Functional HLA-DR epitopes of CEA could be de ned which may serve as components of a vaccination strategy. The other vaccine strategy consisted of the epithelial cell adhesion molecule (Ep-Cam) expressed as a transgene in a viral vector, ALVAC. Patients were immunized over 6 weeks. No anti-Ep-Cam speci c humoral response was induced, but eventually Ep-Cam speci c type 1 T cells were induced. Both vaccines were well tolerated. GM-CSF augmented the responses. A low incidence of GM-CSF antibodies that did not neutralize the effect of GM-CSF was observed.
Wife Anna, 3 sons. 2001-02 chairman for the younger physicians in Uppsala county, 2003 PhD, 2003-04 director of studies at the dpt of oncology in Uppsala, 2005-06 senior lecturer in medical oncology at City Hospital, Nottingham. Since 2007 consultant and since 2008 director for the registrars at the dpt of oncology in Uppsala.
Number of Pages:
LAP Lambert Academic Publishing
0.22 x 0.15 x 0.008 m; 0.263 kg